A small molecule library of pyrido [2,3-d]pyrimidine-2,4-dione derivatives 6-16 was synthesized from 6-amino-1,3-disubstituted uracils 18, characterized, and screened for inhibitory activity against eukaryotic elongation factor-2 kinase (eEF-2K). To understand the binding pocket of eEF-2K, structural modifications of the pyrido[2,3-d]pyrimidine were made at three regions (R 1 , R 2 , and R 3 ). A homology model of eEF-2K was created, and compound 6 (A-484954, Abbott laboratories) was docked in the catalytic domain of eEF-2K. Compounds 6 (IC 50 = 420 nM) and 9 (IC 50 = 930 nM) are found to be better molecules in this preliminary series of pyrido[2,3-d]pyrimidine analogs. eEF-2K activity in MDA-MB-231 breast cancer cells is significantly reduced by compound 6, to a lesser extent by compound 9, and is unaffected by compound 12. Similar inhibitory results are observed when eEF-2K activity is stimulated by 2-deoxy-D-glucose (2-DOG) treatment, suggesting that compounds 6 and 9 are able to inhibit AMPK-mediated activation of eEF-2K to a notable extent. The results of this work will shed light on the further design and optimization of novel pyrido[2,3-d]pyrimidine analogs as eEF-2K inhibitors.
Introduction
Eukaryotic elongation factor-2 kinase (eEF-2K, EC 2.7.11.20) is an atypical Ser/Thr-protein kinase, and is also known as a calcium/calmodulin-dependent protein kinase-III (CaM kinase-III). eEF-2K is not structurally similar to conventional protein kinases, and the structure of eEF-2K has not been reported. eEF-2K phosphorylates eEF-2 at Thr-56 and Thr-58, and inactivates eEF-2, and thus regulates protein synthesis at the elongation step of translation. 1, 2 Nutrients and growth factors inactivate eEF-2K whereas starvation activates it. 3 In 2013, Leprivier et al. 4 demonstrated a crucial role for eEF-2K in protecting normal cells from nutrient deprivation through inhibition of eEF-2, and they suggested how cancer cells could exploit this pathway by activating eEF-2K to adapt to metabolic stress. eEF-2K has been reported to be upregulated in various malignant cells such as breast cancer cells, 5 malignant glioma cells, 6 HL60 leukemia cells, 7 and pancreatic cancer (PaCa) cells, 8 and has been identified as a potential cancer-therapeutic target. 9 Several small molecule inhibitors of eEF-2K have been reported (Fig. 1) , including: Rottlerin 1, which is found to be a non specific and cytotoxic inhibitor, 10 1,3-selenazine analog 2, which is suggested to block phosphorylation of eEF-2 in cells and to react with cysteine residues, 11 the imidazolium derivative (NH125) 3,
12
which does not inhibit eEF-2K in cells, 13, 16 and thieno [2,3-b] pyridine 4, which is an ATP-competitive inhibitor that lacks potency in cells. 14 Recently, high-throughput screens for eEF-2K inhibitors by us, 15 and by Abbott laboratories, 16 revealed thiopyran-dicarbonitrile analog 5, and pyrido-pyrimidinedione derivative A-484954 (compound 6), respectively. A-484954, a small molecule discovered by Abbott, is an ATP-competitive and cell-permeable inhibitor of eEF-2K (IC 50 = 0.28 lM).
We are interested in developing a more potent and selective eEF-2K inhibitor to probe the function of eEF-2K in the regulation of protein synthesis. In this paper, we report the synthesis of a preliminary series of pyrido [2,3-d] pyrimidine-2,4-dione derivatives 6-16 and their inhibitory activity against eEF-2K to explore structure-activity relationships (SAR) of A-484954. Moreover, a homology model has been generated and used to dock compound 6 to provide insight into its binding in the catalytic domain of eEF-2K.
Results and discussion

Chemistry
Pyrido [2,3-d] pyrimidine-2,4-dione derivatives 6-16 were prepared according to Schemes 1-3. Direct alkylation of commercially available uracil derivatives 17 with either ethyl iodide or n-propyl iodide in the presence of 10-15% aqueous NaOH afforded the corresponding 1,3-disubstituted-6-aminouracils 18c-18e in 40-53% yield (Scheme 1). 17 To construct the pyridine ring of pyrido [2,3- d]pyrimidine 6, uracil 18c was treated with the Vilsmeier reagent 19, which was generated in situ from phosphoryl chloride in dimethyl formamide, followed by solvent evaporation and treatment of the residue with triethylamine and cyanoacetamide in ethanol. 18 However, addition of traces of water present in the reaction mixture to the hydrochloride salt 20c resulted in hydrolyzed product 21 in 66% yield, but not the required pyrido [2,3-d] pyrimidine 6 (Scheme 2).
Alternatively, when a catalytic amount of dimethyl formamide and oxalyl chloride were used to prepare the Vilsmeier reagent 22, and the resulting HCl salt 20 was treated with triethylamine and cyanoacetamide in ethanol, compound 6 was isolated in 78% yield over the two steps (Scheme 3). Other pyrido [2,3-d] pyrimidine-2,4-dione derivatives 7, 9, 12-16 were also synthesized using this procedure. Compound 8 was isolated in 47% yield by direct methylation of compound 7 in presence of KO t Bu as a base. On treatment with sodium hydride and p-nitrobenzylbromide, compound 7 resulted in 61% of benzylated product 10 as an off-white solid, which was reduced with SnCl 2 in an ethyl acetate and methanol mixture to afford amine 11 in 70% yield.
Computer homology modeling
The structure of eEF-2K was generated using homology modeling with Dictyostelium myosin heavy chain kinase A (MHCK A) as the template, and compound 6 was docked into the ATP-binding pocket of eEF-2K (Fig. 2 ). The inhibitor 6 is shown in cyan. The protein is shown in cartoon representation, with the hinge region in purple and the Gly-rich loop in blue. The binding of inhibitor 6 involves hydrogen bonds to residues K170, I232 and G234. The hydrophobic cyclopropyl and ethyl groups are buried deep inside the adenine-binding pocket and underneath the Gly-rich-loop, respectively. Docking was performed using Gold5.1 19 with Chem-PLP fitness function. 20 Twenty independent docking attempts were performed for the ligand using generic algorithm. The results of each attempt were ranked according to the ChemPLP fitness score and were virtually inspected. The highest ranked pose of the ligand also happened to be very similar to the most of the high-ranking poses that resulted from the twenty attempts (data not shown The inhibition found for target compounds 6-16, 18c, and 21 against recombinant eEF-2K activity in vitro are summarized in Table 1 . Compound 6 has an IC 50 of 0.42 lM, which differs from the reported value of 0.28 lM (Fig. 3) . 16 This can be accounted for by the difference in assay conditions, where our assay uses 10 lM ATP compared to 5 lM ATP by Chen et compounds 18c and 21 stresses the importance of a pyridine ring for this class of molecules. These results provide new insights, which may aid in the rational design of inhibitors for the kinase.
Cellular activity against eEF-2K
Chen et al. have reported that treatment of various cell lines with compound 6 inhibits eEF-2K activity in a dose-dependent manner, as indicated by reduced levels of phosphorylated eEF-2 (Thr-56). 16 This was observed in human prostate cancer (PC3), human cervical cancer (HeLa), human non-small cell lung cancer (H460 and H1299), and rat glial (C6) cells. Their results are most prominent under conditions of nutrient deprivation (Hanks' Balanced Salt Solution, HBSS), which is known to activate eEF-2K presumably through inhibition of the nutrient-sensitive mTOR pathway. 16, 24 To determine if similar inhibition was observed in breast cancer cells, compounds 6 (IC 50 = 0.42 lM), 9 (IC 50 = 0.93 lM), and 12 (IC 50 >25 lM) were assayed in the MDA-MB-231 cell line.
The level of phosphorylated eEF-2 (Thr-56) was used to estimate the activity of eEF-2K, and as indicated in Figure 4 , results of cellular inhibition are similar to the in vitro kinase assay data. In lowglucose (5.6 mM) media, eEF-2K activity is significantly reduced by the addition of compound 6, to a lesser extent by compound 9, and is unaffected by compound 12 (Fig. 4) . To activate the AMPK-eEF-2K axis, 2-DOG was used. 2-DOG inhibits glycolysis and its production of ATP, thus activating AMPK, which in turn activates eEF-2K through phosphorylation at Ser-398. 25 Similar inhibitory results are observed when eEF-2K activity is stimulated by 2-DOG treatment (Fig. 4) , suggesting that compounds 6 and 9 are able to inhibit AMPK-mediated activation of eEF-2K to a notable extent. tumorigenic breast cells were treated with 75 lM compound 6, 9, or 12 for 1 h in low-glucose media ± 2-DOG, along with the appropriate controls, as described under the Section 4. One set of samples was stimulated with 25 mM 2-DOG (30 min) to activate the AMPK-eEF-2K axis. Cell lysates were then analyzed by Western blotting using antibodies specific for phospho-eEF-2 (Thr-56), total eEF-2, total eEF-2K and pan-Actin as described under the Section 4.
Summary
In summary, a series of pyrido [2,3-d] pyrimidine-2,4-dione derivatives 6-16 was synthesized and screened against eEF-2K inhibitory activity. Ethyl group at R 1 , CONH 2 at R 2 and cyclopropyl at R 3 are found to be optimal, and the pyridine ring and CONH 2 group in 6 are essential for the activity of the studied compounds. Compounds 6 (IC 50 = 420 nM) and 9 (IC 50 = 930 nM) are found to be the best molecules in this preliminary series of pyrido[2,3-d]pyrimidine analogs. eEF-2K activity in MDA-MB-231 breast cancer cells is significantly reduced by compound 6, and to a lesser extent by compound 9. Because there is no eEF-2K crystal structure, the knowledge of the structural features from this preliminary series of analogs along with in-depth computer modeling should yield insights to develop a more potent eEF-2K inhibitor.
Experimental section
Chemistry
Reagents and starting materials including 17a, 17b, and 18f were purchased from various commercial sources and used without further purification unless otherwise stated. All reactions were carried out in oven-or flame-dried glassware under argon. Thinlayer chromatography (TLC) was performed using pre-coated TLC plates with silica gel 60 F 254 (EMD) or with aluminum oxide 60 F 254 neutral. Flash column chromatography was performed using 40-63 lm (230-400 mesh ASTM) silica gel (EMD). Melting points were recorded on a Thomas Hoover capillary melting point apparatus. NMR spectra were recorded on a Varian MR spectrometer. High-resolution mass and liquid chromatography mass spectral data were obtained at the University of Texas at Austin. Compounds were characterized by NMR and HRMS or LCMS.
4.1.1. General procedure for the synthesis of 6-amino-1-alkyl-3-alkylpyrimidine-2,4(1H,3H)-dione (Compounds 18c-18e) A mixture of 6-amino-1-alkyl uracil 17 (1 mmol), sodium hydroxide 10-15% (0.3 mL) and 95% EtOH (0.9 mL) was heated under reflux for 15 min and cooled to room temperature. To the reaction mixture was added the corresponding alkylating agent (R 1 -I) (2 mmol) dropwise. The resulting solution was heated under reflux for 3-8 h. The volatiles were removed under reduced pressure and the residue was partitioned between chloroform/water (2:1 ratio v/v, 9 mL). The organic layer was washed with water, brine, dried over Na 2 SO 4 and evaporated to dryness to give the corresponding 3-substituted 6-amino-1-alkyl-uracils 18c-18e. Unreacted starting material was recovered from the aqueous phase by evaporation to dryness. The obtained crude from organic layer was purified by flash chromatography using 0-10% methanol in dichloromethane.
6-Amino-1-cyclopropyl-3-ethylpyrimidine-2,4(1H,3H)-dione (Compound 18c).
Prepared from 6-amino-1-cyclopropylpyrimidine-2,4(1H,3H)-dione (Compound 17a) and ethyl iodide in 40% yield as a white solid. Mp 186À187°C. 
6-Amino-1-cyclopropyl-3-propylpyrimidine-2,4(1H,3H)-dione (Compound 18d).
Prepared from 6-amino-1-cyclopropylpyrimidine-2,4(1H,3H)-dione (Compound 17a) and propyl iodide in 53% yield as a white solid. Mp 154-155°C. To a solution of dimethylformamide (0.11 mmol) in dichloromethane (1.5 mL) was added oxalyl chloride (0.11 mmol) dropwise at ca. 10°C. The reaction mixture was stirred for 30 min at room temperature. Compound 18 (0.10 mmol) was added to the resulting white suspension and stirred for another 30 min. Volatiles were removed and the crude was taken to the next step without further purification. To the mixture of the crude in dry ethanol (1.0 mL) was added an active methylene compound such as cyanoacetamide, cyanothioacetamide, ethyl cyanoacetate, or malononitrile (0.10 mmol) and then triethylamine (0.12 mmol) dropwise at 0°C. The suspension was allowed to room temperature and stirred for 2 h. Filtered the resulting precipitate and washed with ethanol. In the case of no precipitation, solvent was removed and the obtained crude was purified by flash chromatography (either neutral Al 2 O 3 or silica gel) using 0-10% methanol in dichloromethane. 151.3, 138.4, 105.4, 99.4, 42.1, 25.8, 20.8, 11 .3, 9.9. HRMS: m/z calcd for C 14 A mixture of 10 (27 mg, 0.068 mmol), SnCl 2 (52 mg, 0.273 mmol) in ethyl acetate/methanol (6 mL, 5:6 ratio v/v) was heated at reflux for 12 h. After cooling to room temperature, the solvent was evaporated and the residue was purified by flash chromatography (neutral Al 2 O 3 ) using 0-5% methanol in dichloromethane to isolate 70% of 11 as an off-white solid. Mp >250°C. 
In vitro recombinant kinase inhibition assays
Recombinant human eEF-2K (expressed in bacteria in the absence of k-phosphatase) was purified as described earlier. 22, 23 Inhibitor dose response assays were performed in Buffer A 32 P]ATP. At set time points, 10 lL aliquots were taken and spotted onto P81 cellulose filters (Whatman, 2 Â 2 cm). The filter papers were then washed thrice with 50 mM phosphoric acid (15 min each wash), once with acetone (15 min), and dried. The amount of labeled peptide associated with each paper was determined by measuring the cpm on a Packard 1500 scintillation counter. Kinase activity in each case was determined by calculating the rate of phosphorylation of the peptide (lM/s), and dose-response curves for data conforming to inhibition were fit to Eq. 1.
The parameters are defined as follows: V app obs , apparent rate; V app max , apparent rate in the absence of the inhibitor (maximum rate); V app 1 , apparent rate at saturating concentration of the inhibitor; [i], concentration of the inhibitor; IC 50 , inhibitor concentration required to achieve half maximal apparent rate. When V app obs is converted to percentage maximal activity, V app max is taken as 100.
Cellular kinase inhibition assays
Cell lines and culture conditions
The human breast cancer cell line MDA-MB-231 was obtained from American Type Culture Collection (Manassas, VA). Cells were cultured in DMEM/F12 supplemented with 10% FBS, 50 units/mL penicillin and 50 lg/mL streptomycin. Cell cultures were maintained at 37°C in a humidified incubator containing 5% CO 2 . All cell culture reagents were from Invitrogen or Sigma-Aldrich.
Treatment of cells with stimuli and inhibitors
MDA-MB-231 breast cancer cells were seeded in 6-well plates, and treated when $80% confluent. To activate the AMPK-eEF-2K axis, cells were treated with 2-DOG as follows. Cells were washed with phosphate buffered saline (PBS, pH 7.4), and then preincubated in low-glucose (5.6 mM) DMEM supplemented with 10% FBS for 2 h. Then in the same low-glucose media, cells were initially treated with 75 lM compound 6, 9, or 12 for 30 min, followed by incubation ± 25 mM 2-DOG in the presence of the compounds for an additional 30 min. Treatments with the appropriate DMSO controls were also performed.
Cell lysis and western blot analysis
Following treatments, cells were washed twice in ice-cold PBS (pH 7.4), and lysed in ice-cold Buffer B [50 mM HEPES (pH 7.4), 150 mM NaCl, 1.5 mM MgCl 2 , 1% Triton X-100, 1 mM EGTA, 100 mM NaF, 10 mM Na pyrophosphate, 1 mM Na 3 VO 4 and 10% glycerol], supplemented with PhosSTOP Phosphatase Inhibitor Cocktail (Roche Diagnostics, Indianapolis, IN), complete EDTA-free Protease Inhibitor Cocktail (Roche Diagnostics) and Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific). Lysates were subjected to one freeze-thaw cycle, and then clarified by centrifugation at 15,000g for 15 min. Total protein concentration for each sample was determined by Bradford assay (Bio-Rad Laboratories, Hercules, CA). Western blotting was carried out with
